世界のペプチドワクチン(Peptide Vaccine)市場

KuicK Researchが発行した調査報告書(KUCK501074)
◆英語タイトル:Global Peptide Vaccine Market & Pipeline Insight
◆商品コード:KUCK501074
◆発行会社(リサーチ会社):KuicK Research
◆発行日:2015年1月
◆ページ数:200
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,800 ⇒換算¥201,600見積依頼/購入/質問フォーム
Multi User(社内共有可)USD3,600 ⇒換算¥403,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Peptide vaccines are peptides that exhibit pharmacological properties by activating human immune system rather than showing pharmacologically activity by themselves. They are administered into body to enter in lymph nodes where they induce long lasting immune response. They utilize immune system and develop long term acquired immunity which has capability to prevent future incidences of pathogen attack. Every living cell in human body has surface markers as an instrument to identify self from non-self which is artificially provided by vaccines. When foreign entity penetrates into the body, defence mechanism already triggered by vaccines gets activated to protect from spread of pathogen.

Peptide vaccines also follow the same principles followed by conventional vaccines. It must contain a part of pathogen mimicking protein in their structure. This mimicking molecule enters the body and causes a series of reactions leading to the activation immune system. Body mistook it as an attack by pathogen while in reality it is harmless peptide vaccine. The immune system gets activated and prevents the potential attack done by pathogenic microorganism. The potential of therapeutic drugs in saving lives has been proved and investigators are increasing their focus on development of prophylactic peptide vaccines.

The research and development of peptide vaccines has gained significant momentum in pharmaceutical industry during past decade. The high safety and efficacy levels and minimum side effects is the most important factor for large investments in this segment. Different methods have been found by researchers that offers cost effectiveness to patients besides therapeutic benefits. Pharmaceuticals companies are trying to find innovative methods that could strengthen and diversify their portfolio.

Progress in recombinant DNA technology is the basis of development of peptide vaccine without which current progress has not been achieved by pharmaceutical companies. Market growth of peptide vaccine is dependent on this field and the amount of funds diverged to this segment. To generate more revenues funds invested will increase at significant rates for the development of innovative peptide vaccines. It is expected that the next-generation peptide vaccines presently under investigation would pass through regulatory hurdle, clinical trials and marketed in near future.

Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential.

Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years.

“Global Peptide Vaccine Market & Pipeline Insight” Report Highlights:

• Introduction & Mechanism of Peptide Vaccine
• Peptide Vaccine Market Overview
• Peptide Vaccine Market Dynamics (Drivers, Challenges & Future Outlook)
• Peptide Vaccine Pipeline by Phase, Indication, Company & Country
• Peptide Vaccine Pipeline in Clinical Pipeline: 69
• Majority of Peptide Vaccine in Preclinical Phase: 19
• Competitive Landscape & Patent Analysis

【レポートの目次】

1. Introduction to Peptide Vaccine

2. Mechanism of Peptide Vaccine

3. Global Peptide Vaccine Market Overview
3.1 Current Market Scenario
3.2 Peptide Vaccine Clinical Pipeline Overview

4. Global Peptide Vaccine Market Dynamics
4.1 Market Drivers
4.2 Challenges

5. Global Peptide Vaccine Market Future Prospects

6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III

7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline
7.1 No Development Reported
7.2 Discontinued

8. Competitive Landscape
8.1 Apitope Technology
8.2 BiondVax Pharmaceuticals Ltd
8.3 Circassia
8.4 Eli Lily
8.5 Galena Biopharmaceuticals
8.6 GlaxoSmithKline
8.7 Hyperion Therapeutics
8.8 ImmunoCellular Therapeutics
8.9 Merck
8.10 OncoTherapy Science

Figure 1-1: Different Types of Vaccines
Figure 1-2: Criteria for Ideal Peptide Vaccine
Figure 1-3: Peptide Vaccines Delivery System
Figure 2-1: Mechanism of Peptide Vaccines
Figure 2-2: Mechanism of Live Vaccines
Figure 2-3: Mechanism of Toxoid & Inactivated Vaccine
Figure 2-4: Mode of Action of Peptide Cancer Vaccines
Figure 3-1: Global Peptide Vaccine Pipeline by Phase (%), 2014
Figure 3-2: Global Peptide Vaccine Pipeline by Phase (Number), 2014
Figure 3-3: No Development Reported in Global Peptide Vaccine Pipeline by Phase (%), 2014
Figure 3-4: No Development Reported in Global Peptide Vaccine Pipeline by Phase (Number), 2014
Figure 3-5: Discontinued Peptide Vaccine Pipeline by Phase (%), 2014
Figure 3-6: Discontinued Peptide Vaccine Pipeline by Phase (Number), 2014
Figure 4-1: Global Peptide Vaccine Market Drivers
Figure 4-2: Global Peptide Vaccine Market Challenges



【掲載企業】

Apitope Technology, BiondVax Pharmaceuticals, Circassia, Eli Lily, Galena Biopharmaceuticals, GlaxoSmithKline, Hyperion Therapeutics, ImmunoCellular Therapeutics, Merck, OncoTherapy Science


【レポートのキーワード】

ペプチドワクチン、治験、開発パイプライン、製薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のペプチドワクチン(Peptide Vaccine)市場(Global Peptide Vaccine Market & Pipeline Insight)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆